Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

Medication Talk - Expert Insights on Drug Therapy & Patient Care

Medication Talk - Expert Insights on Drug Therapy & Patient Care artwork

Hormone Therapy for Menopausal Symptoms

Dec 1, 202232 minAudio

Special guest Carolyn J. Crandall, MD, MS, MACP, Professor of Medicine at the University of California, Los Angeles School of Medicine joins us to talk about hormone therapy for menopausal symptoms. Listen in as they clarify when and how to use hormone therapy to manage menopausal symptoms. You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board: Reid B. Blackwelder, MD, FAAFP, Associate Dean of Graduate and Continuing Medical Education at East Tennessee State University Andrea Darby Stewart, MD, Associate Director, Family Medicine Residency at Honor Health Steven E. Nissen, MD, MACC, the Chief Academic Officer at the Heart and Vascular Institute and the Lewis and Patricia Dickey Chair in Cardiovascular Medicine Professor of Medicine at the Cleveland Clinic Lerner School of Medicine at Case Western Reserve University For the purposes of disclosure, Dr. Steven Nissen reports a relevant financial relationship with AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Esperion, Medtronic, Novartis, Pfizer, Silence Therapeutics (grants/research support). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated. Pharmacist’s Letter offers CE credit for this podcast. Log in to your Pharmacist’s Letter account and look for the title of this podcast in the list of available CE courses. Claim Credit 🗪 Send us Fan Mail Email us: ContactUs@trchealthcare.com. The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Medication Talk is a production of TRC Healthcare. Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here. Learn more about our product offerings at trchealthcare.com.

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

NarratorWelcome to Medication Talk, the official podcast of TRC Healthcare, Homo pharmacist letter, prescribers letter, RX Advanced, and the most trusted clinical resources. On today's episode, we'll be listening in as our expert panel clarifies when and how to use hormone therapy to manage menopausal symptoms. Our guest today is Dr. Carolyn J. Crandall from the University of California Los Angeles School of Medicine. You'll also hear practical advice from panelists on TRC's Editorial Advisory Board, Dr. Reed Blackwelder from East Tennessee State University, Dr.

NarratorAndrea Darby Stewart from Honor Health, and Dr. Stephen Nissen from the Cleveland Clinic. This podcast is an extract of TRC's Emerging Recommendations panel webinar. Each month, experts and frontline providers discuss current medication therapy topics and practical recommendations to include in TRC's letter articles. The full webinar originally aired on October 17, 2022.

CE NarratorAnd now, CE information.

NarratorPharmacist Letter offers CE credit for this podcast. Please log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. For the purposes of disclosure, Dr. Steven Nissan reports a relevant financial relationship by receiving grants or research support from AB, Amgen, AstraZeneca, Bristol Meyer Squibb, Eli Lilly, Aspirion, Medtronic, Novartis, Pfizer, and Silas Therapeutics. The other speakers you'll hear have nothing to disclose. All relevant financial relationships have been mitigated. Now let's join TRC editor, Dr.

NarratorLori Dickerson, and start our discussion.

Lori DickersonWe're talking about this now because you'll get questions about using hormone therapy to manage menopausal symptoms, including hot flashes, night sweats, vaginal dryness, etc. And so, Carolyn, to get us started, can you just give us a little bit of background about how the thinking about hormone therapy for menopausal symptoms has shifted over the recent years?

Carolyn J. CrandallSure. So over the last several years, we've had a proliferation of new non-oral hormone options to think of for menopausal symptom treatment. We have a large spectrum now of vaginal types of preparations of estrogen and non-estrogen treatments for vaginal symptoms. We have new insights into the duration of therapy in relation to adverse effects of hormone therapy.

Carolyn J. CrandallAnd finally, we are sure now that we shouldn't be using estrogen either alone or in combination with progestogen for primary prevention of any chronic conditions as a routine. And I think those are the most recent important messages.

Lori DickersonThose are great, Carolyn. And we're definitely going to dig into some of those and talk about the issues that you've brought up. And I'm just curious too, like how have patient requests and questions about hormone therapy shifted over recent years in your practice?

Carolyn J. CrandallI think it's actually changed pretty much in parallel with what I just mentioned. That is, that patients are interested in getting more information about new non-oral options, such as transdermal estrogen preparations. Women are interested in how long to expect to be on hormone therapy and what that might, how that might play into the risks or adverse effects of taking hormone therapy.

Carolyn J. CrandallWhich is what we would term now a prescription bioidentical hormone, that is estradiol that's in a similar form to exactly what your ovary makes, which are many of those preparations are available by prescription that are FDA approved now.

Carolyn J. CrandallAnd so there's a lot of enthusiasm, I think, among my patients recently asking about should I do this? And what do we know about these types of preparations, let's say, in comparison with older conjugated equinestrogen containing regimens.

Lori DickersonI appreciate that overview. And Reed, I actually wanted to call on you as a primary care provider, a family physician. I'm curious about sort of how questions have ebbed and flowed about hormone therapy for menopausal symptoms in your practice over recent years.

Reid B. BlackwelderWell, I think it there has been some ebb and flow, but it's still a pretty consistent issue. And I think the recognition of how dramatically going through menopause impacts how a woman feels and functions is something really to be aware of. And I think the challenge becomes weighing the pros and cons. And what I like most is that I think we have many more options now than what we often would do, which is just the oral agents. And I think that's that's been the fun part is having the conversations about different options.

Reid B. BlackwelderUm I think that's excited a lot of my patients because um they're aware of the risk of oral.

Lori DickersonAnd Andrea Derby Stewart, I wanted to check on you. Um I think you've just joined us, so thank you for joining us. And I'm just curious about a little bit of perspective and background from your women's health practice about hormone therapy for menopausal symptoms and how that's recently shifted.

Andrea Darby StewartYeah, you know, this continues to be a topic of conversation amongst my patients who are perimenopausal as well as menopausal. Um, the thing that I'm uh having some interesting challenges with is that many of my younger colleagues were training in the era of the Women's Health Initiative when everybody decided that hormones were awful and so don't feel comfortable as practicing primary care physicians recommending this as a modality to help treat their patients.

Lori DickersonWell, great. I think that's uh a good reason for us to be writing about this uh with these new guidelines to help folks feel more confident and discussing the pros and cons. And so, um, Carolyn, let's start with when should clinicians and patients consider systemic hormone therapy for menopausal symptoms? And we make a statement in our article to think of systemic HT for bothersome symptoms in healthy patients under age 60 or within 10 years of their last period. And so, I guess first of all, can you comment on that recommendation?

Lori DickersonIs that consistent with the evidence in your current practice?

Carolyn J. CrandallYes, that would be consistent. Um, so uh basically what we think is that women who are younger when they initiate hormone therapy may have um more benefit to risk balance, in other words, more beneficial. And so we like the idea if they uh are under age 60 in terms of that overall um balance of benefit compared to risk or within 10 years of their last period. And and for sure, the standard indication now, the accepted one, is to limit systemic HT to women who have bothersome symptoms.

Carolyn J. CrandallSo menopause isn't a disease. We don't have to treat menopause per se. We leave the decision to the woman in terms of what is bothersome. And she gets to define that, you know, as to her daily life and how much is interference is caused by, let's say, night sweats keeping her up, et cetera, or having trouble uh uh at work, being just miserable and and feeling like her her function is not where she wants it to be.

Lori DickersonSo, and and again, these are the folks on which the benefits of improved quality of life, like you say, these bothersome symptoms um seem to outweigh rare risks such as breast cancer or thrombosis. And uh I think we'll touch a little bit more on some of these risks, but this is I think what you're talking about in terms of quality of life and bothersome bothersome symptoms. Yes, Carolyn? Exactly right. Okay. Very good. And so that's systemic hormone therapy. And then let's just talk a little bit about vaginal estrogen therapy. Uh, and so uh, you know, maybe we can, Carolyn, just differentiate briefly on uh which of which menopausal symptoms are helped with systemic versus vaginal estrogens, and when would you consider a vaginal estrogen?

Carolyn J. CrandallSure. So let's think about um the logical thing first. If a woman only has local vaginal symptoms, then it should be uh uh the best priority to give a local estrogen or uh let's say an FDA-approved, you can include prasterone in that and intra rosa, um local, but local therapy we think of rather than a systemic uh estrogen um or estrogen plus progestin combination.

Carolyn J. CrandallAnd then um they do have minimal absorption if you give these vaginal preparations. Um, that is not to say they have none. So there are some studies that do show increased serum concentrations with these vaginal preparations, but we're but it's going to be a lot lower than with systemic um estrogen therapy. And uh, we are not actually even sure what is the clinical significance of those um uh of that small bump in serum uh estrogen concentrations with vaginal estrogen.

Carolyn J. CrandallYeah. Um yeah, and we expect those symptoms to last basically forever. Um and so we sort of have a different time window involved. Whereas for systemic hormone therapy, those candidates would be women who have hot flashes, night sweats, either or or both. Um, and um we are trying to limit um duration to like five years, no more than five, if we possibly can to control symptoms, just because that's when we especially note that there is an increase, albeit small, but statistically significant increase in breast cancer risk that that we think begins um at the five-year mark, at least with oral um oral estrogen uh plus progestin therapy.

Lori DickersonOkay, we're gonna come back to that. That is uh great overview and um talk a little bit about the duration also, but let's actually talk about breast cancer. Uh, we do have several audience questions coming in about breast cancer survivors, and so we did want to address that in the article. And so we make the uh statement or the recommendation to work with your oncology colleagues if needed. Some breast cancer survivors may opt to use systemic or vaginal hormone therapy as a last resort.

Lori DickersonAnd so, um, Carolyn, just to get your feedback first on that, and then I want to hear from our primary care docs too on how they're addressing this in their practice. So, what are your thoughts on this statement, Carolyn?

Carolyn J. CrandallSure, I do agree with that statement. So we are no longer in an era of paternalistic medicine, right? This every we have shared decision making, and a woman who has breast cancer certainly has the right to say, look, um, these other measures I'm taking that are not estrogen are just not helping me enough. So they may opt to use systemic or vaginal hormone therapy. Um, and and that's certainly their decision. But we do, though, have evidence, and it's important for us to just inform patients that there is potential for increased risk of recurrence if breast cancer survivors are using hormone replacement therapy.

Carolyn J. CrandallAnd that was particularly from the habits trial that uh attention got um called to that. So we just there is uh an increase in potentially an increase in recurrence risk that we ought to tell breast cancer survivors who are thinking about taking systemic hormone therapy. And we probably want to start not systemic, but rather vaginal estrogen. If that were going to be, if the vaginal symptoms are uh are are most distressing, then that's actually a little bit easier conversation in the sense that there's probably less absorption of estrogen when given vaginally.

Carolyn J. CrandallIt's a little trickier with hot flashes where you're wondering about systemic, the need for systemic therapy. And we do have other um non non-uh hormone alternatives that we can offer women with breast cancer um instead of systemic hormone therapy to try to help them with their um vasomotor symptoms, albeit um they may have to uh be off label for that indication. Okay.

Lori DickersonGot it. Andrea, how do you address this with your patients? And you know, I guess you may or may not know the type of breast cancer that they have. Is this would you refer them to oncology or do you discuss it with oncology? What do you think about this recommendation that we have here? Is this directive enough for our readers?

Andrea Darby StewartYeah, I try and work um closely with my oncology colleagues for patients that are experiencing symptoms and have had breast cancer. Um, is certainly I, you know, the hormonal activity of the breast cancer, I think, is um less important to me than it is if I can help manage the patient's symptoms with the least amount of risk to them, meaning that if the oncologist is in agreement, we will start with topical hormonal therapy for um uh for vaginal symptoms.

Andrea Darby StewartAnd uh in terms of systemic therapy, I would echo Dr. Crandall's recommendations for medications that are non-hormonal to begin with if the patient's able to tolerate them and willing to consider those as well. But I would just um certainly want to talk um closely with my oncology colleagues for recommendations.

Lori DickersonGood. Good. Okay, great feedback and overview there. So let's actually move on to talk about which form of hormone therapy should be prescribed. And so, Carolyn, we make the recommendation to use a systemic estrogen, oral, transdermal, or fem ring, vaginal ring for hot flashes and night sweats. Choose a patch, gel, or spray to possibly lower risk of thrombosis. And so um, I guess to start with, using the systemic estrogens, uh, do you how do you make a decision about which one to choose, oral versus transdermal versus vaginal?

Carolyn J. CrandallRight. So um this is really, I think, underappreciated that there that femoring vaginal ring is systemic. And it's basically saying that just because you give something vaginally doesn't mean that it doesn't reach the brain or the breasts or other organs, right? It's basically a dose issue. Uh, if you give a high enough dose, you can suppress people's hot flashes. And that's what happens with that femoring. So we should first of all be very careful not to confuse femoring with the lower dose of estering that we would use for um vaginal atrophy, you know, dysperunia, dryness, itching, and in a vaginal um uh syndrome.

Carolyn J. CrandallThen um, beyond that, for choosing among the oral versus transdermal versus vaginal, I think the issue comes down to this. It's just tricky, where the women's health initiative remains our gold standard because of being the only randomized controlled trial we have of any type of hormone therapy at all in relation to venous thromboembolism and cardiovascular disease and breast cancer. But the problem is, of course, women's health initiative wasn't focused on these younger women with active hot flashes, with hop flashes and night sweats.

Carolyn J. CrandallAnd so the the truth of the matter is, I can't tell a woman for sure that an estrogen patch won't increase the risk of cardiovascular disease. What we do know is that all of the transdermal forms are probably don't have any effect on coagulation, you know, on increasing um coagulation factors. And therefore, we think, although we don't have clinical trials, we think that transdermal preps are maybe associated with less venous thrombal embolism.

Carolyn J. CrandallBut I just we can't really tell women that there's a lower risk of cardiovascular disease or breast cancer just because of a transdermal versus oral. Got it. So it's down to individual preference, as long as women understand the sort of lack of hard outcomes with transdermal compared to, let's say, the women's health initiative conjugated a coin estrogen type of preparation used.

Lori DickersonAnd so um we actually were wondering about in that second sentence there, choose a patch gel or spray to possibly lower risk of thrombosis, if if it should be finished off with, Carolyn, in females at higher risk of thrombosis, or is this a general statement for all women?

Carolyn J. CrandallOkay, yeah, I think it's a general statement that um we can do that uh if we are interested in lowering the risk of thrombosis, and that's independent of whether she is at baseline high risk or not. Clearly, though, if she is at high baseline risk, definitely we want to choose around. Right, right, right. Right.

Lori DickersonAnd I want to differentiate too about um femoring and estering, but before I go there, uh we wondered actually about the second sentence also choose a patch gel or spray. Really, would um a vaginal ring be in that list also uh for lower risk thrombosis, or really are we talking about the topicals, not so sure.

Carolyn J. CrandallOkay, we're not so sure. So I like yeah. Maybe the tweak I would recommend is um choosing a patch, gel, or spray may possibly lower risk of thrombosis. Because I don't honestly know for sure that the trade-off of benefits were risk, you know what I mean? Yeah. So I I like that better.

Lori DickersonThat's a nice tweak. Very good. Okay, now we have this handy little phrase on the next slide about how to remember the difference between uh fem ring and s string. So keep the vaginal ring straight with the phrase a ring is bigger than a string. Now we have used this for years, and it was brought to our attention uh by one of our panelists years ago. Femme ring provides a higher dose for systemic effects, and String is a lower dose for local effects. So that's a handy little way to keep those straight and to remember that the um String is, of course, a local product versus a systemic product.

Lori DickersonAnd so uh just wanted to share that with the group. And um and then Andrea, I just was wanting to hear a little bit from you too, um, about uh your thoughts and in how you help your patients decide on which which formulation to use.

Andrea Darby StewartYeah, you know, it's it's it's an interesting uh discussion. It depends on what the patient has already done in terms of their um uh research. I still um have to battle a little bit uh some of my uh clinician colleagues who place pellets um rather indiscriminately with all kinds of things uh in them. Um so you know, one of our biggest discussions is you know, how much is this going to cost? And that's actually become uh fairly important with my patients.

Andrea Darby StewartUm, in Arizona, patches don't go over very well because they tend to basically sweat off of you in the summer. So I don't have a lot of people who take that up. Um, the gels and sprays tend to be much more expensive, and so we're really looking at oral estrogens. Most of my patients have figured out um uh that conjugated estrogen um is uh may not be what they want. They want something that more closely approximates what their body makes, and so they want to use estradiol, and so we generally go with oral um estradiol as a first start in many of my patients.

Andrea Darby StewartOkay, I don't have many yet. I don't have many people who um want to use um uh the femme ring or systemic symptoms.

Lori DickersonGood, good overview. Thank you for that.

Steven E. NissenSteve, yes, I got a question. Yes. What do you all tell folks that have uh pre-existing cardiovascular disease about estrogen uh supplementation?

Carolyn J. CrandallCarolyn, you want to take that one? Uh sure. I mean, I feel like I take that as a pretty serious reason to try not to use hormone therapy. Um, I try to look if that I'm assuming you mean that the woman is having active hop flashes and nice ones that are really bothersome and then she wants to do something prescription about it. And I so I would try to um to say that if she's absolutely intent on using an estrogen, it should certainly be transdermal.

Carolyn J. CrandallBut I would not recommend that. I would recommend going with a non-estrogen alternative to try to treat those vasomotor symptoms, um, especially because I really feel like that is a contraindication that, for example, the labeling takes quite seriously. Um, and we have numerous trials uh that of uh secondary um cardiovascular disease uh trials of women who've already had pre existing cardiovascular disease.

Lori Dickersonshowing increased risk of um of cardiovascular events um with with a systemic estrogen not the patch per se um right but but um so if you're going if she absolutely wants it absolutely do transdermal but i would not um be in favor of of that type of approach as a as a first line in a woman with cardiovascular disease and so you'd be thinking about an ssri or an snri or a gabapetanoid or a clonidine or something like that instead precise very good very good well thanks for that uh I'm gonna move us along here we do make a recommendation of course for patients with a uterus to add a progestin or use a combo to reduce endometrial cancer or hyperplasia risk and I think that's a pretty straightforward thing and then of course if patients only have a vagin only have vaginal or urinary symptoms to use the low dose vaginal estrogen and a progestin isn't needed.

Lori DickersonSo I think that's uh pretty straightforward uh but we do have a question coming in here um from a community pharmacist that they often see patients with prescriptions for both estradiol vaginal cream uh plus a patch so oral or I'm sorry systemic and uh vaginal products and so Carolyn could you comment on uh on the use of combination this person is asking either does this make sense or should this pharmacist call the prescriber to clarify if the patient needs both?

Carolyn J. CrandallRight that's a great question. So typically if the woman has hot flashes or andor night sweats and vaginal symptoms we would start with a systemic form because there is evidence of improvement in both of those hot flashes night sweats and vaginal symptoms with systemic estrogen therapy. So that makes sense to start that way and give it long enough like a couple of months before deciding whether you should um add on a local vaginal prescription therapy that's that's approved for um treating um vaginal uh symptoms uh we wouldn't start using a combination first generally we would we would try to first see what happens with um systemic alone and then add on a vaginal uh preparation if if we really need to but I did want to mention one thing though that's really important transdermal estrogen by itself unopposed by the progestogen causes like somewhere around 30% per year incidence of of endometrial hyperplasia so um don't don't think that transdermal is always quote unquote safer um it's okay to add to if you add the progestogen it's fine right but be careful to think of it as a as a systemic um treatment it does uh resolve basomotor symptoms and um that's important to recognize um had another question coming in actually from Andrea Derby Stewart was wondering about perspective on DHEA vaginal suppositories that many of her patients prefer this to prescribe topical estrogens and so what are your thoughts on this uh Carolyn?

Carolyn J. CrandallYeah so um DHEA also known as Prasterone um can it is a is uh is a recently approved more recently approved um vaginal preparation for the vaginal symptoms so it's local for vaginal menopausal symptoms and um it's actually uh seems to be very effective but again is not completely free of raising serum estradiol concentrations in the same way as other vaginal estrogens do.

Carolyn J. CrandallSo um and then there are the cost implications as well that can sometimes come up. So there's no particular reason to think it is inferior to any of the vaginal estradiol preparations um but there may be cost implications and they may also um it may also increase um serum estradiol concentration just slightly just like the other um vaginal estrogens may we also don't have any long-term endometrial safety information about um about intra rosa or or for that matter any of the vaginal estrogens really have only been examined for two years in in clinical trials and yet the symptoms last a long time so we need to be very careful to counsel women to immediately report spotting etc with any of these these preparations that's a good counseling tip too um so let's actually talk about how long to use hormone therapy and um also how to stop and so we make the point in our article Carolyn that there's no quote right duration or age cutoff but to start to think about stopping hormone therapy after four to five years and as you mentioned previously that's when breast cancer risk may slightly increase if using an estrogen and a progestin um but of course many women will have hot flashes that continue for over a decade.

Lori DickersonSo just curious about your thoughts on this recommendation and is this in in general how you approach the situation? Start discussion.

Carolyn J. CrandallYeah definitely that's how I approach the situation so I mean more than half of women have uh hot flashes and night sweats for more than seven years. This is not just a a rare occurrence. So we try we base that four to five year mark again on the gold standard from women's health initiative of estrogen plus progestogen and it's logical to extend that to other combinations of estrogen plus progestine that are used systemically. So also with the patch as well. And um uh so the the problem though is that when you want to stop a patch, it's a little more complicated, right?

Carolyn J. CrandallBecause you can't just fool around and cut patches in half and you know indiscriminately mess around. So it's a little difficult in terms of figuring out how to wean down how to taper. And it turns out that it doesn't really make a difference to the symptoms in the long term whether you whether you wean or not whether you taper or not. It's just sort of a it might help with with um with preventing recurrence of the symptoms in the short term but over the long term we shouldn't really get very concerned about weaning and and what's the right way to wean because in the long term it doesn't make much difference.

Lori DickersonRight to sort of let the patient drive that to some degree about how how quickly they'd like to wean and I do get your point too though about patches and would we have to prescribe a new lower strength of a patch for the weaning and that can get expensive et cetera so uh that's that's great feedback. And Andrea I'm just curious about your approach here in talking to women about stopping or weaning.

Andrea Darby StewartYeah you know I've started I you know just like any other medication I try and set a timeline for how long we'd like to be on the medication talk a little bit about the risks and the benefits of any type of you know longer term duration of use and then we generally just start to do a slow wean and I think that that's more of a a psychic benefit than anything else in terms of helping people feel as if they are not just going to suddenly be put back in the position that they were in uh previously having um ongoing hot flashes and it helps them kind of feel more comfortable with the process.

Andrea Darby StewartI think it's mostly just about talking to your patients.

Lori DickersonCommunication very good all right we have a couple of questions coming in that are not addressed in the article but Carolyn lots of questions coming in about black cohosh for menopausal symptoms.

Carolyn J. CrandallSo what is what are your thoughts about about that as an option right um so we all I think we all as prescribers are sympathetic to the notion that people want non-prescription slash natural kind of approaches to treating symptoms but unfortunately there's a double there's a big challenge here in the menopause field and and the big issue is that there's a 50% reduction in hofflashes just from taking a placebo in many of the clinical trials.

Carolyn J. CrandallSo we we don't have good evidence that anything other than the estrogen um and some other non some other prescription therapies like SNRS is all right we don't have any evidence that the non-prescription approaches including black kohosh are better than placebo now if the woman takes black kohosh and says I felt better maybe it is a placebo effect but we have to believe her because she did she says she feels better. So it's a tricky thing and we want to make sure that of course that we feel like our patients are that we're that we're displaying that we're listening and having an intent conversation here.

Carolyn J. CrandallBut the issue is that nothing is better than placebo that is an over the counter type of approach for reducing hot flushes and night sweats women don't like to hear that it's disappointing and I totally get it but I would not recommend Black Kohash or any other non-prescription therapy at this moment and we need to tell our patients to always look for placebo comparisons when they're hearing a bunch of hype on some new clinical trial of an over the counter remedy We hope you enjoyed and gained practical insights from listening into this discussion.

NarratorNow that you've listened you can receive CE credit from Pharmacist Letter just log into your Pharmacist Letter account and look for the title of this podcast in the list of available CE courses. If you're not yet a Pharmacist Letter subscriber find out more about our product offerings at trchealthcare dot com. Be sure to follow or subscribe rate and review this show in your favorite podcast app. It helps spread the word about our show and is a great way for you to let us know how we're doing you can also reach out to provide feedback or make suggestions by emailing us at contact us at trchealthcare dot com.

NarratorThanks for listening to Medication Talk

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Navigating Obesity Treatment

    Nov 1, 202634 minAudio

    Listen in as our expert panel walks through today’s full range of obesity treatment options - from older agents like orlistat and phentermine/topiramate to the latest GLP-1 therapies - and how to match the right...

    Credit the people on this episode

  2. Feed Drop: Toxic Yellow Oleander in Weight Loss Products

    Oct 15, 202624 minAudio

    A bonus episode from our sister show, Natural Medicines: Evidence in Practice. Weight loss supplements labeled tejocote, Nuez de la India, or Brazil seeds have been found to contain toxic yellow oleander, and as few as...

    Credit the people on this episode

  3. Managing Poisonings

    Oct 1, 202633 minAudio

    Poisonings are a significant public health concern - in 2024 alone, U.S. poison centers received over 2 million reported exposures. Listen in as our expert panel of toxicologists and poison-center specialists discusses...

    Credit the people on this episode

  4. Decoding the Lipid Guidelines

    Sep 1, 202633 minAudio

    Listen in as our expert panel breaks down what clinicians need to know about the 2026 dyslipidemia guidelines, such as the role of lipoprotein a, apolipoprotein B, and coronary artery calcium scoring. Plus, you'll walk...

    Credit the people on this episode

  5. Estimating Kidney Function in Chronic Kidney Disease

    Aug 1, 202633 minAudio

    Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You’ll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust...

    Credit the people on this episode